

Table 3. Multivariate prediction model of the association between patients' clinical and surgico-pathological characteristics and overall survival.

CHARACTERISTICS	CATEGORY	BIVARIATE ANALYSIS		FINAL FITTING MODEL	
		HR	%ΔHR	ADJ HR (95% CI)	P-VALUE
Recurrence time	≤6 vs. >6 months	7.16	-	7.23 (3.87 – 13.51)	<0.01
Age	≥51 vs. <51 years	7.66	7%	-	-
Parity	Nulliparous vs. Multiparous	7.04	-2%	-	-
Menopausal status	postmenopause vs. Premenopause	7.79	9%	-	-
BMI	≥25 vs. <25 kg/m ²	7.13	-1%	-	-
Upfront treatment	PDS vs. NACT	7.98	11%	1.27 (0.73 – 2.21)	0.39
Ascites	Nulliparous vs. Multiparous	6.46	-10%	1.46 (0.87 – 2.44)	0.15
FIGO stage	Stage 3 & 4 vs. Stage 1 & 2	6.59	-8%	-	-
Surgical debulking status	Optimal vs. Suboptimal	6.83	-5%	-	-

Abbreviations: Adj HR, Adjusted hazard ratio; 95% CI, 95% confidence interval; %ΔHR, the percentage change in HR; BMI, body mass index; CA, cancer antigen; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; NACT; neoadjuvant chemotherapy; PDS; primary debulking surgery; Type I includes endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, and low-grade serous carcinomas; Type II includes high-grade serous carcinomas.